Doctor,Examining,Patient,Skin,Moles,With,Dermoscope

Dermatology Research and Treatment Development

Improving quality of life for dermatology patients

Individuals suffering from dermatological conditions often experience psychological distress, which exacerbates their physical symptoms. Alleviating this suffering drives our team’s commitment to work with you to bring new treatments to patients in need.

CRO services with extensive dermatology experience and capabilities

The PPD™ clinical research business of Thermo Fisher Scientific has a deep understanding of the challenges of dermatology drug development.

0 +

Dermatology trials we have conducted

0 +

Patients we have enrolled

0 +

Investigators we have worked with around the world

Put the patient first in atopic dermatitis trials

By layering in the lived patient experience, our indication champions take trial strategy to the next level.

Expanding patient access to dermatology clinical trials

We are positioned to help sponsors complete dermatology studies rapidly and successfully through our extensive experience in dermatology clinical trials, an international network of sites experienced in key indications like psoriasis, atopic dermatitis and HS, access to a large database of potential trial participants, and a commitment to tailored trial design. Through our proprietary network of sites, our customers can receive 50–100% of their entire trial enrollment from one accountable solution, delivered by clinical research locations that operate uniformly across the globe.

Our dermatology team has established stable connections with most patient advocacy groups (PAGs) active in dermatology diseases, proving effective for the successful execution of clinical trials from a patient-centric protocol design until the final effective and timely recruitment.

Discover seven strategies to increase patient diversity in dermatology clinical trials

Our dermatology clinical research experience

We have a deep understanding of the challenges of dermatology drug development and a global network of dedicated board-certified dermatologists, highly experienced professionals and a range of investigator sites to support trials for organizations of all sizes across a broad range of indications. Our dermatology experience includes work with biopharmaceutical, biotech, medical device and academic organizations.

In the past five years, our dermatology team has performed trials for 28 pharmaceutical and biotech companies across all regions, including North America, South America, Europe and Asia-Pacific.

Learn more about our dermatology experience and capabilities

Challenges of dermatology drug development

We have experience with the decentralized model in dermatology studies. The dermatology team uses tailored clinical trial design solutions, including e-consent, home-health and other digital solutions, to support patient and site centric solutions without compromising quality or efficiency. The decentralized model shows promise in mitigating some of the burden and cost of traditional methods while preserving the quality of oversight. Going forward, we expect more sponsors to promote the use of hybrid solutions with a combination of site-based and remote activities as they seek to meet the evolving needs of patients around the world.

As the clinical landscape continues to evolve, we have the resources to conduct dermatology clinical trials in many ways, including traditional, hybrid and fully decentralized models. Our experience with eCOA, ePRO, telemedicine approaches, hybrid virtual trials, e-consents, electronic medical records and remote source document verification (rSDV), among others, has enabled us to rapidly convert traditional trials to decentralized trials during the COVID-19 pandemic. Our experience, combined knowledge and access to patients has allowed us to quickly pivot in response to unexpected and changing situations, providing the support and insight needed to address heightened risks and keep clinical trials on track.

Due to the reliance on patient and clinician reported outcomes for most primary and secondary endpoint data in atopic dermatitis and psoriasis studies, data consistency is crucial. To ensure data consistency across all raters at study sites, robust training and certification checks are necessary. We prioritize providing comprehensive training to the sites to ensure accurate data collection.

Broad indication expertise in dermatology clinical studies

We continue to build out areas of expertise to ensure we provide sponsors with the highest quality, most efficient clinical study design, management and operations. We continue to expand site networks to enable rapid enrollment by focusing on high-performing site relationships and seeking new ways to overcome seasonal changes in individual countries by leveraging sites in both the Northern and Southern hemispheres so that subjects can be enrolled continuously. Our comprehensive dermatology experience spans a broad range of indications including: 

  • Atopic Dermatitis
  • Psoriasis
  • Hidradenitis suppurativa
  • Alopecia
  • Pruritus & Prurigo Nodularis
  • Chronic Urticaria (CSU and CIndU)
  • Pemphigus vulgaris
  • Bollus Pemphigoid
  • Epidermolysis bullosa
  • Dermatomyositis
  • Cutaneous Lupus
  • Aesthetics

Along with multiple other skin manifestations…

Meet the dermatology team

Sophia Tono, M.D.
Medical Director, dermatology pharmacovigilance. Dermatologist
Rose Blackburne, M.D., MBA
Vice President, global head of general medicine/dermatology.
Michael E. Kuligowski, M.D., Ph.D., MBA, FAAD
Vice President, medical and scientific strategy, dermatology. Dermatologist
Maria Marcano Bozo
Maria Marcano Bozo
Medical Director, pharmacovigilance and medical science services. Dermatologist

Dermatologic conditions represent a leading cause of disability worldwide. It’s an exciting time in dermatology product development where unmet medical needs in psoriasis, atopic dermatitis and other diseases can be addressed with novel molecules, monoclonal antibodies, Janus kinase inhibitors (JAK) and other products that work across the inflammatory pathway.

Additional resources

Contact us